Cannabis Canada Daily: Cronos Group shares slide on Q1 revenue miss, earnings forecast

Aurora Cannabis got the nod once again by Luxembourg as the country’s exclusive supplier of medical cannabis. This will mark the second order …

Shares of Cronos tumble following Q1 revenue miss, declining earnings forecast

Shares of Cronos Group tumbled Thursday after the company reported its fiscal first-quarter results. Investors soured on the Toronto-based company’s stock after its CFO noted that the company’s adjusted earnings before certain items would decline over the course of 2019, but should ramp up for “accelerated growth” in 2020. Cronos reported first-quarter revenue of $6.5 million, down from the $7 million analysts were expecting. Meanwhile, the company sold 1,111 kilograms of cannabis in the quarter, up 122 per cent from the same period a year earlier. Gross margins rose to 54 per cent from 47 per cent a year ago. Cronos CEO Mike Gorenstein added revenue is expected to remain “relatively stable” in the second quarter, then accelerate in the back half of the year.

Lack of strong policy options from Ottawa shifting investor interest to U.S. pot market from Canada

Despite being the first developed country to legalize cannabis, a lack of forward-thinking government policies has meant Canada’s cannabis industry is operating with “one hand tied behind their back,” according to one Bay Street investor and an early supporter of the legal marijuana industry. Neil Selfe, chief executive of Toronto-based Infor Financial Group, told BNN Bloomberg on Thursday the Canadian government legalized cannabis without a lot of forethought to capital allocation, products, brands, and distribution. That’s resulted in Canadian firms lagging behind their U.S. counterparts in terms of both revenue and investors’ interest. Selfe added the so-called cannabis bubble is beginning to shrink as investors turn their focus to the U.S. and other markets.

Canadian support for legal cannabis, edibles market wanes amid shaky legalization rollout: Study

It turns out Canadians’ outlook for legal cannabis is less rosy that previously believed. A new study co-authored by Dalhousie University and the University of Guelph found support for recreational cannabis among Canadians has dropped since the drug was legalized last year following the shaky roll-out of legal pot and a still-robust black market. The study found half of Canadians support the legalization of recreational cannabis, down from about 69 per cent back in 2017. Meanwhile, uncertain sentiment surrounding legalization has grown to 20 per cent of the country, up from about seven per cent two years ago. Interest in cannabis-infused edible products — expected to hit store shelves later this fall — has also waned with about 36 per cent of people polled saying they plan to buy edibles when they become available on the market, down from 46 per cent in 2017.

Luxembourg re-ups with Aurora as main medical pot supplier

Aurora Cannabis got the nod once again by Luxembourg as the country’s exclusive supplier of medical cannabis. This will mark the second order Aurora has supplied for the government of Luxembourg. While the Luxembourg medical cannabis market is relatively tiny compared to say, Germany, it adds another name to the growing list of nations Aurora supplies. The deal is the most recent of many moves the Edmonton-based producer has made in international medical markets. Last month, Aurora announced it had been chosen to help supply the German market with medical cannabis. And late last year, the company formed a partnership with a Mexican pharmaceutical distributor and manufacturer to supply that country’s market.

Canopy Growth secures a big chunk of PharmHouse growing space

Canopy Growth, the biggest cannabis company in the world, still needs some more domestic supply. The Smiths Falls, Ont.-based company has tapped PharmHouse to provide 30 per cent of its Leamington, Ont.-based flowering space as part of an offtake agreement. Using Canopy Growth’s genetics, PharmHouse will grow cannabis for 18 months in its greenhouse, returning the raw flower back to Canopy Growth to be sold under its brands. The deal is expected to produce 25,000 kilograms to 45,000 kilograms of cannabis per year. Interestingly, PharmHouse is a 49 per cent-owned joint venture of Canopy Rivers, the venture capital arm of Canopy Growth. PharmHouse previously announced a cultivation agreement with TerrAscend Canada Inc. to supply products from 20 per cent of the facility’s flowering space.



— The approximate value of the purchase order delivered by Aleafia Health to an unnamed Canadian province, the biggest such delivery in the cannabis producer’s history.

Embedded Image

Cannabis Canada is BNN Bloomberg’s in-depth series exploring the stunning formation of the entirely new — and controversial — Canadian recreational marijuana industry. Read more from the special series here and subscribe to our Cannabis Canada newsletter to have the latest marijuana news delivered directly to your inbox every day.

Related Posts:

  • No Related Posts

Future Prospects on Cannabis Oil Market to Grow at a CAGR of +11% by 2024: Top Companies …

Future Prospects on Cannabis Oil Market to Grow at a CAGR of +11% by 2024: Top Companies Analysis SpaceX, Planet Labs, OneWeb, Sierra …

Image result for Cannabis Oil

The report on Cannabis Oil provides an in-depth analysis and fundamental data along with the complete details regarding the Global Cannabis Oil. The global market is experiencing a relatively high growth rate due to increased healthcare spending, a high incidence of chronic diseases, sleep disturbances among patients, and increased perception of treatment for depression.

Cannabis Oil market is anticipate to grow at a CAGR of +11% during the forecast period. The research report studies the Cannabis Oil market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Get Sample PDF@

Key Player Profile: SpaceX, Planet Labs, OneWeb, Sierra Nevada Corporation, OHB AG, Spire, etc.

The report also implements primary and secondary research techniques for gathering the most crucial pieces of professional information, and applies a number of industry-best techniques upon the data for projecting the future state of the global Cannabis Oil market. Based on current market development, the report includes an analysis of how activities such as mergers and shapes the market’s future.

Key Questions Answered in Report:

  • What are factor which lead this market to next level?
  • What will the market Demand and what will be Growth?
  • What are the upcoming opportunities to Cannabis Oil market in future?
  • What are the strengths of the key players?
  • What are the major key of Cannabis Oil market?

Get best discount on this report@

A section containing exceptional detailed data about all the influential players operating in the market has also been included in the report, giving readers and enterprises access to information such as challenges faced by the companies, the growth strategies implemented, the recent developments reported by them, and the financial and business overview of the company.

Revenue shares, service offerings and contact information of each of the companies has also been stated with maximum details. With the help of these details, a to the point overview of the competitive landscape of the market is covered in the report, expected to give the readers a clear idea of strategies that are providing most promising returns to companies

this study, the years considered to estimate the market size of Cannabis Oil are as follows:

History Year: 2014-2018

Base Year: 2018

Estimated Year: 2019

Forecast Year 2019 to 2025

Complete Report at

Table of Content (TOC):

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with key players

Chapter 4 Global Cannabis Oil Market Analysis, Trends, Growth Factor

Chapter 5 Cannabis Oil Market Application and Business with Potential Analysis

Chapter 6 Global Cannabis Oil Market Segment, Type, Application

Chapter 7 Global Cannabis Oil Market Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Cannabis Oil Market

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusio

If you have any special requirements, please let us know, we will offer you the report as per your needs.

About QYReports:

We at, QYReports , a leading market research report publisher accommodate more than 4,000 celebrated clients worldwide putting them at advantage in today’s competitive world with our understanding of research. Our list of customers include prestigious Chinese companies, multinational companies, SME’s and private equity firms whom we have helped grow and sustain with our fact-based research. Our business study covers a market size of over 30 industries offering unfailing insights into analysis to reimagine your business. We specialize in forecasts needed for investing in a new project, to revolutionize your business, to become more customer centric and improve the quality of output.

Contact us:


Jones John

(Sales Manager)

Address-204, Professional Center,

7950 NW 53rd Street, Miami, Florida 33166

Contact number :+(1) 786-292-8164

Related Posts:

  • No Related Posts

TDAM launches three ETFs

Three new ETFs from TD Asset Management Inc. (TDAM) have begun trading on the Toronto Stock Exchange, the company announced Thursday.

Two ETFs launch this week focused on U.S. cannabis

The funds, from Evolve and Horizons, will trade on NEO

  • By: Staff
  • April 17, 2019April 18, 2019
  • 14:19

Related Posts:

  • No Related Posts

Cronos Group (CGC) leads the cannabis sector lower after reports a revenue miss

The company said it has been selected by the Luxembourg Health Ministry to be exclusive supplier of a second … Market leader Canopy Growth Corp.

The Dow Jones Industrial Average DJIA, -0.52% fell 400 points in early trade, after Trump claimed that China “broke the deal.” The major indexes have fallen at least 2% this week as anxiety about the deepening trade dispute unsettled investors.

The two main cannabis exchange-traded funds have fallen in sympathy. The Horizons Marijuana Life Sciences ETF and the ETFMG Alternative Harvest ETF have both declined more than 4% in the week so far.

In regulatory news, the National Association of Attorneys General sent a letter to congressional leadership on Wednesday, urging them to pass the SAFE banking act, a bipartisan bill aimed at protecting financial institutions that serve the cannabis industry in states that have legalized.

The letter from 38 state and territory attorneys general asks that Congress approve “the SAFE Banking Act or similar legislation that would provide a safe harbor for depository institutions that provide a financial product or service to a covered business in a state that has implemented laws and regulations that ensure accountability in the marijuana industry.”

The letter notes that the current state of affairs, in which companies are forced to handle large amounts of cash, has made it more difficult to track revenue for tax purposes as well as for regulatory compliance purposes.

From Canada comes a new study that has found that support for legal recreational cannabis is falling in Canada, while uncertainty about it is growing. The study, conducted by The Dalhousie University, found 50.1% of Canadians said they accept legalization, down from 68.6% in a 2017 study carried out before legalization in October of last year, according to media reports.

At the same time, 20.3% said they were uncertain, up from just 6.9% in 2017.

“We were surprised to see that Canadians are actually less enthusiastic about edibles since cannabis became legal last fall,” said Dr. Sylvain Charlebois, author of the report.

The survey comes ahead of the legalization of edibles in Canada in October. Only 36% of those surveyed said they would purchase cannabis-infused food products, down from 46% in the 2017 survey.

“With cannabis edibles being legalized in October, we are frankly curious about the decrease in interest expressed by survey respondents,” said Brian Sterling, one of the report’s co-authors. “We would like to understand that shift. It will be interesting to see how this perspective evolves as cannabis and infused products become more commonplace.”

Cronos Group Inc. shares CRON, -7.56%CRON, -6.76% fell 8%, after the company reported first-quarter earnings. Cronos surprised investors with a small profit of C$427,812 ($317,380), or 48 cents a share, that comes after a loss of C$1,085, or 1 cent a share, in the year-earlier period.

Revenue rose to C$6.470 million from C$2.945 million a year ago. The FactSet consensus of six analysts was for a loss per share of 3 cents and revenue of C$6.390 million. The company sold 1,111 kg of cannabis in the quarter, up from 501 kg in the year-earlier period. Revenue per gram sold came to C$5.73 compared with C$5.67 a year ago.

Aurora Cannabis Inc. ACB, -1.83%ACB, -1.55% shares fell 3.6%. The company said it has been selected by the Luxembourg Health Ministry to be exclusive supplier of a second delivery of medical cannabis to the Duchy. The company said the initial bid quantities are small, but that it showed its ability to work in complex, restricted markets.

Aleafia Health Inc. ALEF, +3.61%ALEF, +3.61% said it welcomes changes to cannabis licensing announced by the Canadian healthy ministry, that seek to align the approach with other regulated sectors. The ministry will require all applicants to have a fully built site that meets all of the regulatory requirements at the time of application, and will complete a review of existing applications to speed up the process.

“These changes will alleviate product shortages and application backlogs, while spurring job creation in local communities as more completed facilities become operational,” said Aleafia Chief Executive Geoffrey Benic. Shares were up 1.5%.

Elsewhere in the sector, Aphria Inc. APHA, -2.31%APHA, -1.71% was down 3.5% and Hexo Corp. HEXO, -2.38% was down 3.6%. Market leader Canopy Growth Corp. CGC, -2.10%WEED, -1.47% was down 3.3%. Tilray Inc. TLRY, +0.75% fell 2.5%.

Medical cannabis retailer MedMen Enterprises Inc. shares MMNFF, +1.58% were down 1.2%. Valens GroWorks Corp. VGWCF, -3.61% was down 2.5%.

The Horizons Marijuana Life Sciences ETF HMMJ, -2.43% was down 2.8%, and the ETFMG Alternative Harvest ETF MJ, -1.33% was down 2.2%.

The ETFMG Alternative Harvest ETF (MJ) was trading at $34.20 per share on Thursday afternoon, down $0.47 (-1.36%). Year-to-date, MJ has gained 5.15%, versus a 7.93% rise in the benchmark S&P 500 index during the same period.

MJ currently has an ETF Daily News SMART Grade of C (Neutral), and is ranked #56 of 85 ETFs in the Global Equities ETFs category.

This article is brought to you courtesy of MarketWatch.

Related Posts:

  • No Related Posts

Investor Ideas Potcasts, Cannabis News and Stocks on the Move May 9th (NYSE: CGC) (TSXV …

Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) announced today that it has signed an offtake agreement with PharmHouse Inc., a 49 per …

Delta, Kelowna, BC – May 9, 2019 ( Newswire), a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, release today’s edition of potcastsCM – cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

Investor Ideas Potcasts, #Cannabis News and Stocks on the Move May 9th (NYSE: $CGC) (TSXV: $RIV.V) (NYSE: $ACB) (CSE: $AHG.C) (CSE: $THC.C)

Hear Investor ideas cannabis potcast on iTunes

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of “potcasts”, looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast I look at a few of the day’s earlier announcements.

But first, Gov. Doug Burgum has signed a bill into law making North Dakota the 25th state in the nation to eliminate the threat of jail time for possession of small amounts of marijuana.

HB 1050 reclassifies possession of up to a half ounce of marijuana by adults 21 and older as an infraction punishable by no jail time and a maximum fine of $1,000. Previously, it was a misdemeanor punishable by up to 30 days in jail in addition to a fine. The bill also reclassifies penalties for possession offenses involving amounts greater than a half ounce, and it calls on the Legislative Assembly to “consider studying the implications of the potential adoption of an initiated measure allowing the use of recreational marijuana.” A more detailed summary of HB 1050 is available here.

“This legislation is far from ideal, but it is a substantial step in the right direction,” said Matthew Schweich, deputy director of the Marijuana Policy Project. “It is very encouraging to see a conservative state like North Dakota acknowledge and rectify the injustice of jailing people for possession of small amounts of marijuana. Lawmakers can no longer ignore public support for marijuana policy reform, which is growing quickly in every part of the country.”

Gov. Burgum also recently signed a series of bills designed to expand and improve access to medical marijuana for patients registered under North Dakota’s existing medical marijuana law, which voters approved in 2016.

As well, after the first year as a unified national industry association, and with the framework of cannabis legalization firmly established, the Cannabis Council of Canada has announced its newly elected Board of Directors. As the association embarks on its second year of operations, the Board is tasked with supporting its members and continuing to work with key stakeholders on the advancement of the legal cannabis industry in Canada and around the world.

C3’s general membership represents almost 90% of Canada’s legal cannabis industry, and has elected the following individuals to the Board:

Megan McCrae – Aphria Inc., Board Chair

John Fowler – The Supreme Cannabis Company, Vice Chair, Adult Use

Philippe Lucas – Tilray, Vice Chair, Medical

Darren Karasiuk – Aurora Cannabis Inc.

Alison Gordon – 48 North Cannabis Co.

Jeff Jacobson – Cronos Group

Jeff Ryan – Canopy Growth Corporation

Ray Gracewood – Organigram

Isabelle Robillard – HEXO Corp.

Gerald Proctor – Sundial Growers Inc.

Ruth Chun – Newstrike/UP Cannabis

The board members bring a wealth of diverse experience in the following areas: scientific research, marketing and communications, strategy and innovation, market analysis, business development, government relations, policy development, law and non-profit.

Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) announced today that it has signed an offtake agreement with PharmHouse Inc., a 49 per cent-owned joint venture of Canopy Rivers Inc. (TSXV: RIV) (OTC: CNPOF). Under the terms of the agreement, PharmHouse has agreed to allocate high quality cannabis flower from an additional 20 per cent of the flowering space available at its Leamington greenhouse facility over the next three years.

Boasting 1.3 million square feet of greenhouse grow space, and leveraging the resources of Canopy Growth, Canopy Rivers and its joint venture partner have worked diligently since October 2018 to prepare the facility for licensing. PharmHouse will leverage Canopy Growth’s genetics – selected and supplied by the Company – and flower will be returned to the Company to be sold under Canopy Growth’s diverse brands and banners. Under the terms of the new offtake agreement, PharmHouse is committed to producing GMP-certified, high quality cannabis flower within 18 months of its cultivation license and the flower must comply with the Company’s high standards for cannabis quality. GMP, or Good Manufacturing Practices, certification is the internationally recognized system to ensure all produced goods meet the highest consumer health and safety standards, allowing the Company to export the flower to its international divisions. Including this new agreement, 30 per cent of PharmHouse’s total flowering space has been committed to Canopy Growth.

“We have witnessed Canopy Rivers and its joint venture partner pour their hard work into the PharmHouse facility in Leamington and couldn’t be more satisfied with how it has turned out,” said Bruce Linton, Chairman & Co-CEO of Canopy Growth Corporation and Chairman & CEO of Canopy Rivers. “We expect the same for the flower quality that PharmHouse will be providing to Canopy Growth. This is further evidence that the ecosystem model we had hoped for from Canopy Rivers is demonstrating its value and this new offtake agreement with PharmHouse speaks to how well we are managing our numerous assets.”

Following that, one of America’s most influential tastemakers, best-selling author and business executive Martha Stewart will speak at the World Cannabis Congress (WCC) in Saint John, NB being held this June 16-18. Stewart is an example of big brands and high-profile personalities that are entering into the cannabis space as outdated stigma gives way to mainstream growth opportunities.

“I look forward to sharing my knowledge and experience in the lifestyle space with this tailored audience,” says Stewart. “As I begin to collaborate on products for the CBD market, and as the demand for these types of product grows, I’m very interested in the conversations and connections at this event.”

The World Cannabis Congress is renowned for convening major influencers, thought leaders, policy makers and government officials to help shape and advance the cannabis industry worldwide. The curated, invite-only event is one of the most sought-after tickets in the industry, bringing together the right people in the right place at the right time to drive the industry forward. Stewart’s participation comes at a time when interest in CBD and cannabis-infused food and beverages have become hot topics, with Canada set to legalize edibles later this year.

“Martha Stewart is the perfect example of where the cannabis industry is headed,” says Derek Riedle, Publisher of Civilized. “This is an industry that’s quickly moved from the backroom to the boardroom. We’re able to attract phenomenal, top-tier talent and experts like Martha Stewart because of the legitimacy the cannabis industry is amassing, as well as the calibre of the audience we have in the room at WCC. We can’t wait to hear what Martha Stewart has to say about expanding her brand in this new market.”

Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB) announced today that the Company, through its wholly owned subsidiary Aurora Deutschland, has been selected by the Luxembourg Health Ministry as the exclusive supplier in a public bid to supply a second delivery of medical cannabis to Luxembourg.

Under the terms of the bid, the medical cannabis produced will be sold to Luxembourg’s Division de la Pharmacie et des Medicaments, representing the second time the Company has received an order directly from the Luxembourg government. While the initial bid quantities are small, the award confirms Aurora’s position as a trusted and preferred supplier to international jurisdictions and reflects the Company’s ability to work with local governments and regulators in complex, restricted markets.

“We are proud to continue serving as the exclusive supplier of medical cannabis to the Luxembourg Health Ministry,” said Neil Belot, Chief Global Business Development Officer. “Adding to the many achievements of our European team, which also includes our recent selection as one of only three companies to establish domestic production in Germany, our expanded supply agreement with Luxembourg reinforces Aurora’s ability to act as a trusted partner that can readily meet the complex needs of diverse international markets.”

Alternate Health Corp., (CSE:AHG) (OTCQB:AHGIF), an international leader in technology and extraction solutions for the regulated cannabis industry, announced today a key step forward in the Company’s pharmaceutical-grade CBD product manufacturing strategy, having signed a joint venture agreement with Oltecate Enterprises, a COFEPRIS-licensed Mexican CBD distributor, with an eye for expansion throughout Latin America.

Alternate Health’s expansion into the Latin American CBD market complements the Company’s recent US$20 million acquisition of Blaine Labs, previously announced on May 5, 2019. With 23 years of experience producing FDA-approved and cGMP-certified medical products, Blaine Labs is uniquely positioned to manufacture a wide range of CBD products that meet international export standards. As Alternate Health rapidly expands Blaine Labs CBD product line, the Company expects Mexico to be a key growth market for future sales and a jumping off point for further distribution throughout Latin America.

“With this acquisition, we are taking another major step in consolidating the global CBD market,” says Howard Mann, CEO of Alternate Health. “We now boast the addition of nation-wide Mexican CBD licenses to our hemp-based medical product assets, including extraction, distribution and product development.”

Based in Tecate, Baja California, Mexico, Oltecate’s headquarters are strategically located along the US-Mexican border with California. Oltecate currently holds four federal CBD licenses issued by COFEPRIS, the Mexican equivalent of the U.S. Food and Drug Administration (FDA). Currently, Mexican law prohibits cannabis and hemp cultivation and extraction, but imports of CBD products are legal with the appropriate COFEPRIS license. These licenses allow Alternate Health to import and distribute products in numerous growing markets across Mexico.

THC BioMed Intl Ltd. (CSE: THC) THC BioMed reported that it has entered into an agreement with the BC Liquor Distribution Branch (“BCLDB”) to supply a number of its products exclusively to British Columbia.

The agreement was entered into after the BC Liquor Distribution Branch (BCLDB) met with THC BioMed management and toured THC’s flagship facility in Kelowna B.C.

The BCLDB will provide purchase orders to THC BioMed for the product quantities listed in the appendix to the agreement three months in advance of the available supply month.

  • THC BioMed Ltd. has committed to:
    • Supplying all produced dried flower product intended for the non-medical market, exclusively to the BCLDB until December 2019;
    • Maintaining Wholesale Cost incl. Excise as listed in the appendix to the Agreement until December 2019; and
    • Supplying the product as per the quantities and schedule listed in the appendix to the Agreement.

THC BioMed has agreed to exclusively supply the BCLDB with several flower strains in 3.5-gram and 7-gram formats until December 2019.

“We are proud that our products will be featured in our home province of BC. We continue to strive to produce cannabis products that are pure, clean and potent. We also look forward to launching THC Kiss, a pure organically produced cannabis beverage, when regulations permit” commented John Miller, CEO and president of THC BioMed.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment

Sign up to get the news alerts including the daily podcast and transcript for Investor ideas podcasts

Subscribe to the new cannabis podcast series:

Or visit


To hear more podcasts visit: podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About – News that Inspires Big Investing Ideas is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.

Disclaimer/ is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at

Follow us on Social Media



Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directories

Related Posts:

  • No Related Posts